N-(isoquinolin-6-yl)-2-morpholino-2-phenyl-acetamide | 1173806-71-7

• 英文名称: N-(isoquinolin-6-yl)-2-morpholino-2-phenyl-acetamide
• 英文别名: N-isoquinolin-6-yl-2-morpholin-4-yl-2-phenylacetamide
• CAS: 1173806-71-7
• 化学式: C₂₁H₂₁N₃O₂
• 分子量: 347.417
• InChiKey: FXLBDKPQKLPACL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  吗啉 、 2-chloro-2-phenyl-N-(isoquinolin-6-yl)acetamide 在 potassium iodide 作用下， 以 甲醇 为溶剂， 反应 4.67h， 生成 N-(isoquinolin-6-yl)-2-morpholino-2-phenyl-acetamide
  参考文献：
  名称：

  6-And 7-amino isoquinoline compounds and methods for making and using the same

  摘要：

  提供了影响、抑制或减少激酶作用的6-和7-氨基异喹啉化合物。还提供了包括治疗有效量的6-和7-氨基异喹啉化合物和药用可接受载体的制药组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或疾病条件，如癌症、肥胖和青光眼的各种方法。

  公开号：

  US20090186917A1

文献信息

• 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
  申请人：deLong Mitchell A.

  公开号：US20100144713A1

  公开（公告）日：2010-06-10

  6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了影响、抑制或减少激酶作用的6-和7-氨基异喹啉化合物。还提供了包括治疗有效量的6-和7-氨基异喹啉化合物和药学上可接受的载体的制药组合物。还提供了使用这些化合物和/或组合物影响癌症、肥胖症和青光眼等疾病状态或病症的各种方法。
• 6-and 7-amino isoquinoline compounds and methods for making and using the same
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US08153654B2

  公开（公告）日：2012-04-10

  6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了6-和7-氨基异喹啉化合物，它们可以影响、抑制或减少激酶的作用。还提供了包括治疗有效量的6-和7-氨基异喹啉化合物和药学上可接受的载体的制药组合物。还提供了使用这些化合物和/或组合物来影响癌症、肥胖症和青光眼等疾病状态或病情的各种方法。
• 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME
  申请人：AERIE PHARMACEUTICALS, INC.

  公开号：EP2546238A1

  公开（公告）日：2013-01-16

  6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-and 7-amino isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了可影响、抑制或减少激酶作用的 6-和 7-氨基异喹啉化合物。还提供了包括治疗有效量的 6-和 7-氨基异喹啉化合物和药学上可接受的载体的药物组合物。还提供了使用这些化合物和/或组合物影响癌症、肥胖症和青光眼等疾病状态或病症的各种方法。
• 7-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME
  申请人：AERIE PHARMACEUTICALS, INC.

  公开号：EP2546237A1

  公开（公告）日：2013-01-16

  6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-and 7-amino isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了可影响、抑制或减少激酶作用的 6-和 7-氨基异喹啉化合物。还提供了包括治疗有效量的 6-和 7-氨基异喹啉化合物和药学上可接受的载体的药物组合物。还提供了使用这些化合物和/或组合物影响癌症、肥胖症和青光眼等疾病状态或病症的各种方法。
• US8153654B2
  申请人：——

  公开号：US8153654B2

  公开（公告）日：2012-04-10